Stream
Stories
-
FDA grants traditional approval for pembrolizumab and Keytruda QLEX for TMB-H solid tumors
On October 16, 2026 the FDA granted traditional approval to pembrolizumab (Keytruda) or pembrolizumab and berahyaluronidase alfa-pmh (Keytruda QLEX) for patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors defined as ≥13 mutations/megabase. In the KEYNOTE-158 study, 220 patients with TMB ≥13 mut/Mb had an objective response rate of 36% (95% CI: 30, 43) and 58% achieved a duration of response of at least 12 months.
-
Lilly breaks ground on $5 billion Richmond facility to produce API and finished medicines
Eli Lilly and Company announced on Oct. 22, 2026 that it broke ground on a $5 billion manufacturing facility just west of Richmond, Virginia, the company's first fully integrated site to produce both active pharmaceutical ingredients and finished antibody-drug conjugates. The new plant is expected to create 650 high-wage jobs and about 1,800 construction jobs during construction.
-
Vertex registers Phase 3b study of Povetacicept vs Sibeprenlimab in Immunoglobulin A Nephropathy
Vertex Pharmaceuticals Incorporated has registered a Phase 3b, open-label, single-arm study to evaluate participant experience with Povetacicept injection via autoinjector compared to Sibeprenlimab injection via prefilled syringe in adults with Immunoglobulin A Nephropathy. The study plans to enroll 40 participants, with a start date of October 23, 2026 and primary completion date of December 12, 2027.
-
Hoffmann-La Roche registers Phase III trial of enicepatide versus tirzepatide in type 2 diabetes
The study, led by Hoffmann-La Roche with Chugai Pharmaceutical as collaborator, plans to enroll 948 participants and begin on December 1, 2026. It will evaluate the efficacy and safety of enicepatide, a glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor (GLP-1/GIP) receptor agonist (RA), compared with tirzepatide in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on oral glucose-lowering medications.
-
Sanofi registers Phase 3 trial of combination SARS-CoV-2 and influenza vaccine in older adults
The study, led by Sanofi, plans to enroll an estimated 6000 participants aged 60 and older to assess the safety and immunogenicity of a combined SARS-CoV-2 recombinant spike and high-dose inactivated influenza vaccine with Matrix-M adjuvant. It is planned to begin on November 9, 2026, with primary completion expected on December 28, 2027.
-
Pfizer registers Phase 3 trial of atirmociclib plus giredestrant in ER+ HER2- early breast cancer
The study plans to enroll 3800 participants and randomize them 1:1 to receive atirmociclib plus giredestrant or placebo plus giredestrant. It is scheduled to begin on December 1, 2026, with a primary completion date of April 13, 2032.
-
ScandiBio registers Phase 3 trial of CMA2 in gout
The study plans to enroll 336 participants and is expected to start in October 2026, with primary completion projected for February 2027. This will be a randomised, double-blind, placebo-controlled, multi-center study to evaluate the efficacy, safety, and tolerability of Combined Metabolic Activator (CMA2) including N-acetyl-L-cysteine, L-carnitine-L-tartrate, nicotinamide, and L-serine versus placebo.
-
Merck posts results of Phase III KEYNOTE-522 trial in triple negative breast cancer
The study enrolled 1,174 participants and compared pembrolizumab plus chemotherapy to placebo plus chemotherapy as neoadjuvant therapy, followed by pembrolizumab or placebo as adjuvant therapy. Results were first posted on ClinicalTrials.gov on October 22, 2026.
-
Medtronic reports positive real-world registry results for Sphere-9 and PulseSelect at APHRS 2026
Medtronic said the APEX registry included 1,050 patients with atrial fibrillation treated with the Sphere-9 catheter, reporting a 1.1% major complication rate. The REAL PULSE registry included 1,160 patients and reported a 100% acute success rate with a 0.09% acute major complication rate.
-
Jiangsu Hansoh registers Phase 3 trial of HS-10382 in newly diagnosed Ph+ CML-CP
The study, led by Jiangsu Hansoh Pharmaceutical Co., Ltd., plans to enroll 408 participants and has a planned start date of December 2026. It evaluates the efficacy of oral HS-10382 versus investigator-selected TKIs-imatinib, nilotinib, dasatinib, and flumatinib-in adult patients with newly diagnosed Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia.
-
Azafaros registers open-label extension trial of nizubaglustat in rare lysosomal disorders
The study, NCT07885917, is an open-label roll-over trial to evaluate long-term safety and tolerability of nizubaglustat (AZ-3102) in participants with Niemann-Pick Disease Type C, GM2 Gangliosidosis, GM1 Gangliosidosis, and Gaucher Disease Type 3. It plans to enroll 218 participants, with a start date of December 10, 2026, and primary completion by April 1, 2030.
-
Kite registers Phase 3 trial of anitocabtagene autoleucel in newly diagnosed multiple myeloma
The study, iMMagine-4, plans to enroll 600 participants and has a planned start date of January 2027. It plans to compare the safety and efficacy of anitocabtagene autoleucel versus standard of care therapy in participants with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant.